| 货号 | 2204S |
| 供应商 | CST |
| 背景 | Bortezomib (C19H25BN4O4), a boronic acid dipeptide, is a specific, potent, and reversable proteasome inhibitor that has also been shown to have a stabilizing effect on proteins that inhibit cell survival and cell cycle progression, such as p53 (1,2). Researchers have demostrated that bortezomib inhibits activation and nuclear translocation of NF-κB, subsequently decreasing early tumor survival (3). The increase in bortezomib-stablilized, misfolded, and ubiquitinated proteins that interfere with cell survival and other important pathways further support its anti-tumor effects (3). |
| 存放说明 | -20C |
| 参考文献 | 1 . Williams, S.A. and McConkey, D.J. (2003) Cancer Res 63, 7338-44. 2 . Poulaki, V. et al. (2007) Invest Ophthalmol Vis Sci 48, 4706-19. 3 . Mimnaugh, E.G. et al. (2004) Mol Cancer Ther 3, 551-66. |
Chemical structure of Bortezomib.硼替佐米的化学结构。 | |
Western blot analysis of extracts from NIH/3T3 cells, untreated (-) or treated (+) with Bortezomib (100 nM, 6 hr), using Ubiquitin Antibody #3933 (left), p53 (1C12) Mouse mAb #2524 (middle), and β-Actin (13E5) Rabbit mAb #4970 (right).Western blot分析NIH/3T3细胞提取物，未处理(-)或用硼替佐米(100 nM, 6小时，+)处理，使用的抗体是：Ubiquitin Antibody #3933（左图），p53 (1C12) Mouse mAb #2524（中间），β-Actin (13E5) Rabbit mAb #4970（右图）。 | |
Western blot analysis of L363 cells, untreated (-) or treated (+) with Bortezomib (24 hr) as indicated, using K48-linkage Specific Polyubiquitin Antibody #4289.Western blot分析L363细胞，未处理(-)或用硼替佐米(24小时，+)按照指示处理，使用的抗体是：K48-linkage Specific Polyubiquitin Antibody #4289。 |
